DΞGeN Diary: Week of April 9th

What's up you DΞGeNerate's, miss you all. It has been a minute since I have really started to get this back going, but I want to try to get back to where we were a few months ago.

I am going to start off slow and get back into the groove of things, but want to start doing a weekly outlook or review that gets sent out every Sunday night. So here we are.

First off, how about Jon Rahm winning The Masters?! Are you kidding. Not only was he highly favored to win, but he went out and dominated. Gotta say though, it was nice to see Brooks and Speith near the top of the leaderboard again.

The market right now is sending mixed signals to everyone. Bonds are pointing towards a recession, but credit is holding up. Everything is upside down.

Treasuries and equities both gained last month. Gold neared an all time high on rate cut bets. Yet, investors are still putting cash into money market funds. The difference between the best and worst ticket on SPX topped 20% points in March, which is double the average in the past two decades... Everyone is all over the place in terms of "predictions" for year end forecasts.

“Markets look confused and contradictory between the asset classes,” said Peter Chatwell, head of global macro strategies trading at Mizuho International Plc. “They are pricing in the tail risk of a recession, but not as an imminent event.”

Here is the Economic Calendar for the Week:

*CPI Data comes out on Tuesday, so please be careful.

WhaleStream Watch Of The Week

SRPT - Sarepta Therapeutics

A "highly unusual", "aggressive", and "written" alert came across WhaleStream flow on Thursday that caught my eye.

SRPT $152.50 Call. Exp. 05/05/2023 for a total premium of $433.64K

Sarepta plummeted a few weeks ago after they announced they were seeking input from a panel on a new gene therapy drug AFTER they told investors they were not going to go the advisory committee route.

Citi's Bitritto-Garg wrote in a research note hat "the change in plans to hold an AdCom [advisory committee] may not be indicative of a meaningful change in FDA's position on the filing, which we believe has been favorable."